189 related articles for article (PubMed ID: 36522800)
1. 'Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research'.
Passalacqua MI; Rizzo G; Santarpia M; Curigliano G
Expert Opin Investig Drugs; 2022 Dec; 31(12):1291-1310. PubMed ID: 36522800
[TBL] [Abstract][Full Text] [Related]
2. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
3. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Xie X; Lee J; Iwase T; Kai M; Ueno NT
Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape.
Uliano J; Nicolò E; Corvaja C; Taurelli Salimbeni B; Trapani D; Curigliano G
Expert Rev Clin Pharmacol; 2022 Dec; 15(12):1399-1413. PubMed ID: 36317756
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
6. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives.
Kim J; Fahmy V; Haffty BG
Expert Rev Anticancer Ther; 2024 May; 24(5):211-217. PubMed ID: 38502143
[TBL] [Abstract][Full Text] [Related]
7. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
Fremd C; Jaeger D; Schneeweiss A
Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
[No Abstract] [Full Text] [Related]
8. The landscape of systemic therapy for early stage triple-negative breast cancer.
Lu JY; Alvarez Soto A; Anampa JD
Expert Opin Pharmacother; 2022 Aug; 23(11):1291-1303. PubMed ID: 35818711
[TBL] [Abstract][Full Text] [Related]
9. GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells.
Mani C; Tripathi K; Omy TR; Reedy M; Manne U; Palle K
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166300. PubMed ID: 34748904
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
11. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
12. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
13. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
14. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract][Full Text] [Related]
15. Current landscape of personalized clinical treatments for triple-negative breast cancer.
Zhang J; Xia Y; Zhou X; Yu H; Tan Y; Du Y; Zhang Q; Wu Y
Front Pharmacol; 2022; 13():977660. PubMed ID: 36188535
[TBL] [Abstract][Full Text] [Related]
16. Triple Negative Breast Cancer: A Tale of Two Decades.
Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer.
Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH
Tumori; 2013; 99(4):545-54. PubMed ID: 24326846
[TBL] [Abstract][Full Text] [Related]
18. mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Mo W; Liu Q; Lin CC; Dai H; Peng Y; Liang Y; Peng G; Meric-Bernstam F; Mills GB; Li K; Lin SY
Clin Cancer Res; 2016 Apr; 22(7):1699-712. PubMed ID: 26546619
[TBL] [Abstract][Full Text] [Related]
19. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
20. Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development.
Tarantino P; Antonarelli G; Ascione L; Curigliano G
Expert Opin Investig Drugs; 2022 Jun; 31(6):499-513. PubMed ID: 34569405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
